{"id":25154,"date":"2025-03-26T07:05:49","date_gmt":"2025-03-26T06:05:49","guid":{"rendered":"https:\/\/k2info.w.uib.no\/?p=25154"},"modified":"2025-03-26T07:05:49","modified_gmt":"2025-03-26T06:05:49","slug":"onlinearrangement-om-forskningsverktoy-for-barnekreft","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/nb_no\/2025\/03\/26\/onlinearrangement-om-forskningsverktoy-for-barnekreft\/","title":{"rendered":"[:no]Onlinearrangement om forskningsverkt\u00f8y for barnekreft[:en]Online event on childhood cancer research tools[:]"},"content":{"rendered":"<p>[:no]Den 24. april 2025 fra 15:00 CET til 15:45 CET, arrangerer Innovative Health Initiative et nettbasert arrangement &laquo;I samtale med&#8230; ITCC-P4&raquo; som vil fokusere p\u00e5 verkt\u00f8yene som prosjektet utviklet for \u00e5 hjelpe til med \u00e5 akselerere forskning p\u00e5 barnekreft.<\/p>\n<p>IHIs senior vitenskapelige prosjektleder, Nathalie Seigneuret, vil moderere diskusjonen mellom:<br \/>\n\u2022 Gilles Vassal, administrerende direkt\u00f8r for ITCC-P4 og pediatrisk onkolog ved Gustave Roussy Comprehensive Cancer Center<br \/>\n\u2022 Lou Stancato, VP for muliggj\u00f8rende teknologier og leder for sjeldne pediatriske sykdommer ved Indiana Biosciences Research Institute og adjunkt klinisk assisterende professor i pediatri ved Indiana University School of Medicine<br \/>\n\u2022 Nicole Scobie, pasientrepresentant, leder av Accelerate, styremedlem i Coalition Against Childhood Cancer (CAC2), og president emeritus ved Zo\u00e94Life<\/p>\n<p>Registrer deg her: <a href=\"https:\/\/www.ihi.europa.eu\/news-events\/events\/conversation-itcc-p4\">In conversation with&#8230; ITCC-P4 | IHI Innovative Health Initiative<\/a><\/p>\n<p><strong>Om ITCC-P4-prosjektet <a href=\"https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-24885 alignright\" src=\"https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1-300x222.jpg\" alt=\"\" width=\"300\" height=\"222\" srcset=\"https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1-300x222.jpg 300w, https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1-768x569.jpg 768w, https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1-624x462.jpg 624w, https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1.jpg 810w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/strong><\/p>\n<p>Kreft er fortsatt den ledende d\u00f8ds\u00e5rsaken ved sykdom hos barn i Europa. Likevel er kreft hos barn relativt sjeldne og har en annen natur enn de fleste kreftformer som finnes hos voksne, noe som gir spesielle utfordringer for kreftforskere.<\/p>\n<p>ITCC-P4-prosjektet har levert et system sammensatt av verkt\u00f8y som kan hjelpe forskere fra b\u00e5de offentlig og privat sektor med \u00e5 identifisere lovende molekyler som kan danne grunnlaget for nye legemidler for \u00e5 behandle barnekreft. Dette vil hjelpe forskerne til \u00e5 prioritere hvilke legemiddelkandidater som skal testes p\u00e5 barn og fremskynde tiden det tar f\u00f8r disse medisinene kommer til klinikken.<\/p>\n<p>Verkt\u00f8ysettet inkluderer validerte modeller, en unik database som skisserer omfattende molekyl\u00e6re data om kreft i barndommen, en internasjonal konsensus om de prekliniske dataene som trengs for \u00e5 st\u00f8tte utvikling av pediatrisk legemiddel, og en ny metodikk for \u00e5 definere relevansen av visse legemiddelm\u00e5l basert p\u00e5 litteraturanalyse. Et av n\u00f8kkelresultatene var utviklingen av PDX-modeller for mange barnekreftformer, fra de mer vanlige kreftformene til tilbakefall og sjeldne kreftformer. PDX-modeller er laget av en kombinasjon av pasientavledet tumorvev og musemodeller, og de har vist seg \u00e5 v\u00e6re en effektiv m\u00e5te \u00e5 studere kreft hos voksne p\u00e5, men er enn\u00e5 ikke mye brukt i barnekreftforskning.<\/p>\n<p>ITCC-P4 har opprettet en ny ideell organisasjon som vil fortsette \u00e5 tilby disse vitale verkt\u00f8yene og ekspertisen til kreftforskere fremover.<\/p>\n<p>Finn ut mer om registreringen her: <a href=\"https:\/\/europa.eu\/!MNBRkD\">https:\/\/europa.eu\/!MNBRkD<\/a><\/p>\n<p>Se p\u00e5 v\u00e5res nettside:\u00a0 <a href=\"https:\/\/itccp4.com\/\">https:\/\/itccp4.com\/<\/a><\/p>\n<p>Vil du holde deg oppdatert p\u00e5 alle IHIs aktiviteter?<\/p>\n<ul>\n<li><a href=\"https:\/\/www.ihi.europa.eu\/news-events\/newsletter\">Sign up to our newsletter<\/a><\/li>\n<li><a href=\"https:\/\/www.linkedin.com\/company\/727919\/\">Connect with us on LinkedIn<\/a><\/li>\n<li><a href=\"https:\/\/mastodon.social\/@IHIEurope\">Follow us on Mastodon<\/a><\/li>\n<li><a href=\"https:\/\/bsky.app\/profile\/ihieurope.bsky.social\">Follow us on Bluesky<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/k2info.w.uib.no\/files\/2025\/03\/in.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-25155\" src=\"https:\/\/k2info.w.uib.no\/files\/2025\/03\/in.png\" alt=\"\" width=\"195\" height=\"61\" \/><\/a><\/p>\n<p>&nbsp;[:en]On 24 April 2025 from 15:00 CET to 15:45 CET, the Innovative Health Initiative is organising an online event \u2018<em>In conversation with\u2026 ITCC-P4\u2019<\/em> that will focus on the tools that the project developed to help accelerate childhood cancer research.<\/p>\n<p>IHI\u2019s senior scientific project manager, Nathalie Seigneuret, will moderate the discussion between:<\/p>\n<ul>\n<li>Gilles Vassal, chief operating officer of ITCC-P4 and paediatric oncologist at Gustave Roussy Comprehensive Cancer Center<\/li>\n<li>Lou Stancato, VP of enabling technologies and leader of paediatric rare diseases at Indiana Biosciences Research Institute and adjunct clinical assistant professor of pediatrics at the Indiana University School of Medicine<\/li>\n<li>Nicole Scobie, patient representative, chair of Accelerate, board member of the Coalition Against Childhood Cancer (CAC2), and president emeritus at Zo\u00e94Life<\/li>\n<\/ul>\n<p>Register here: <a href=\"https:\/\/europa.eu\/!MNBRkD\">https:\/\/europa.eu\/!MNBRkD<\/a><\/p>\n<p><strong>About the ITCC-P4 project<a href=\"https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-24885 alignright\" src=\"https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1-300x222.jpg\" alt=\"\" width=\"300\" height=\"222\" srcset=\"https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1-300x222.jpg 300w, https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1-768x569.jpg 768w, https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1-624x462.jpg 624w, https:\/\/k2info.w.uib.no\/files\/2025\/02\/BKF-Hilde-Eide-Frivillig-med-barn-800x600-1.jpg 810w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/strong><\/p>\n<p>Cancer is still the leading cause of death by disease seen in children in Europe. Yet childhood cancers are relatively rare and are different in nature to most cancers found in adults, presenting particular challenges to cancer researchers.<\/p>\n<p>The ITCC-P4 project has delivered a system composed of tools that can help researchers from both the public and private sector to identify promising molecules that could form the basis of new drugs to treat childhood cancer. This will help researchers to prioritise which drug candidates to test in children and accelerate the time it takes for those medicines to reach the clinic.<\/p>\n<p>The toolkit includes validated models, a unique database outlining comprehensive molecular data about childhood cancers, an international consensus on the preclinical data needed to support paediatric drug development, and a new methodology to define the relevance of certain drug targets based on literature analysis. One of the key results was the development of\u00a0 PDX models of many childhood cancers, from the more common forms of cancer to relapses and rare cancers.\u00a0 PDX models are made from a combination of patient-derived tumour tissue and mouse models, and they have proven to be an effective way of studying cancer in adults but are not yet widely used in childhood cancer research.<\/p>\n<p>ITCC-P4 has set up a new non-profit organisation which will continue to provide these vital tools and expertise to cancer researchers going forwards.<\/p>\n<p>Find out more and register here: <a href=\"https:\/\/europa.eu\/!MNBRkD\">https:\/\/europa.eu\/!MNBRkD<\/a><\/p>\n<p>Visit the ITCC-P4 website:\u00a0 <a href=\"https:\/\/itccp4.com\/\">https:\/\/itccp4.com\/<\/a><\/p>\n<p>Want to stay up-to-date on all of IHI\u2019s activities?<\/p>\n<p><a href=\"https:\/\/k2info.w.uib.no\/files\/2025\/03\/in.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-25155\" src=\"https:\/\/k2info.w.uib.no\/files\/2025\/03\/in.png\" alt=\"\" width=\"195\" height=\"61\" \/><\/a>[:]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[:no]Den 24. april 2025 fra 15:00 CET til 15:45 CET, arrangerer Innovative Health Initiative et nettbasert arrangement &laquo;I samtale med&#8230; ITCC-P4&raquo; som vil fokusere p\u00e5 verkt\u00f8yene som prosjektet utviklet for \u00e5 hjelpe til med \u00e5 akselerere forskning p\u00e5 barnekreft. IHIs&hellip;<\/p>\n<p class=\"more-link-p\"><a class=\"more-link\" href=\"https:\/\/k2info.w.uib.no\/nb_no\/2025\/03\/26\/onlinearrangement-om-forskningsverktoy-for-barnekreft\/\">Read more &rarr;<\/a><\/p>\n","protected":false},"author":5375,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[],"class_list":["post-25154","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts\/25154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/users\/5375"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/comments?post=25154"}],"version-history":[{"count":1,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts\/25154\/revisions"}],"predecessor-version":[{"id":25156,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts\/25154\/revisions\/25156"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/media?parent=25154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/categories?post=25154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/tags?post=25154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}